Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of long-acting antibody therapy as monotherapy and combination therapy for moderate to severe active ulcerative colitis
CTR20263997Phase 2Active
- Sponsor
- 辟埃赛医药科技（上海）有限公司
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SPY001 in autoimmune colitis, sponsored by 辟埃赛医药科技（上海）有限公司. Started Nov 2026; status: active.
02
Drugs
SPY001
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20263997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263997.